Optimizing Clinical and Economic Outcomes in the Management of Moderate-to-Severe Rheumatoid Arthritis

A continuing medical education activity sponsored by NAMCP and AAMCN.

This activity is an archive from the live session from the 2019 Spring Managed Care Forum. If you participated in the live session, you are not eligible for continuing education credits from this archive.

This activity is valid from June 1, 2019 to August 1, 2020

Instructions for CME/CNE: Complete the pre-test, listen to the audio and view the slides, complete the post test, complete the evaluation form and hit submit. You will be asked to enter your name and email address on the pre-test, evaluation and post-test. If you close your internet browser without completing the post test, you will have ONE more opportunity to complete. A score of 70% must be achieved on the post test to receive continuing education credits. If you do not pass the post test after two attempts, you will not be eligible to try again. Once you complete the evaluation form and score 70% or higher on your post test, you will automatically be given your certificate.

To print or save your certificate, you will need to click on the “download” button and either print or save.


Audience: This activity is intended for healthcare professionals practicing in managed care environments.

This presentation is supported by educational grants from
Bristol-Myers Squibb and Sanofi Genzyme and Regeneron Pharmaceuticals

Rheumatoid arthritis (RA) is a long-lasting autoimmune disorder that occurs when the immune system mistakenly attacks the body's own tissues, effecting an estimated 1.3 million people in the United States. It typically results in warm, swollen, and painful joints, and pain and stiffness often worsen following rest. Most commonly, the wrist and hands are involved, with the same joints typically involved on both sides of the body. The disease may also result in a low red blood cell count, inflammation around the lungs, and inflammation around the heart. Diagnosis is done through examination, including x-rays and ultrasounds, and blood testing for certain indications. There is no cure for RA thus the focus of treatment is to control the disease, it’s symptoms, and to prevent joint damage during flare ups where the pain and inflammation are much worse. Some patients experience “remission” where the pain and inflammation disappear or almost disappear. Despite the currently available non-biologic and biologic therapies, only about 1/3 of patients treated for RA ever achieve clinical remission. Other patients experience continuous disease progression and disability. In addition, many patients will have an inadequate response or can become intolerant to the widely used anti-TNF therapies. Consequently, the patient’s health-related quality of life may continue to be significantly reduced. Fortunately, new and emerging treatment strategies, including IL-6 receptor antagonists, have shown improved efficacy and safety in RA.

Upon completion of this activity, participants will be able to:

  • Explore efficacy and safety profiles of current and emerging therapies for the treatment of moderate-to-severe RA for achieving individualized treatment goals

  • Examine the role of anti-citrullinated protein antibodies (ACPAs), among other RA biomarkers, as part of the pathophysiology of RA

  • Analyze treatment regimens for moderate-to-severe RA based on ongoing monitoring of disease activity, functional status, treatment response, and other patient-specific factors

  • Interpret results of decision support tools with health plan affiliated rheumatology professionals to improve outcomes for patients with RA

  • Examine strategies to monitor and manage adverse events associated with current and emerging biologic therapies indicated for the treatment of patients with moderate-to-severe RA in order to maximize tolerability and adherence to therapeutic regimens


Faculty: Roy Fleischmann, MD MACR
Co-Medical Director Metroplex Clinical Research Center
Clinical Professor of Medicine
University of Texas Southwestern Medical Center


Dr. Fleischmann serves on an advisory board for AbbVie, BMS, Lilly, and Pfizer. He serves as a consultant for AbbVie, Amgen, BMS, Lilly, and UCB. He has received grant/research support from AbbVie, Amgen, BMS, Genentech, Lilly, and UCB. His presentation has been peer reviewed for any bias.
  Planning Committee:
Bill Williams, MD has no relevant financial relationships to disclose.
Jeremy Williams has no relevant financial relationships to disclose.
Will Williams has no relevant financial relationships to disclose.
Jacqueline Cole, RN, MS, CMCN has no relevant financial relationships to disclose.

NAMCP and/or the presenter has copyright or has received permissions for use of materials provided in this activity.

Accreditation & Designation
The National Association of Managed Care Physicians (NAMCP) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

NAMCP designates this enduring material for a maximum of 1 AMA PRA Category I creditsTM.

The American Association of Managed Care Nurses (AAMCN) is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation (ANCC).

Nurses who complete this activity and achieve a passing score will receive 1 hour in continuing
nursing credit.

This activity has been approved by the American Board of Managed Care Nursing for 1.0 contact hour toward CMCN recertification requirements.

This presentation is supported by educational grants from
Bristol-Myers Squibb and Sanofi Genzyme and Regeneron Pharmaceuticals

NAMCP and/or this website does not provide medical advice, diagnosis or treatment. NAMCP does not endorse or imply endorsement of the content on any linked website. This website is to be used as an informational resource. With any health related concern, consult with your physician or healthcare professional.

Click Here To Continue